Pyxis Oncology (NASDAQ:PYXS – Free Report) had its price target upped by HC Wainwright from $4.00 to $7.00 in a research report sent to investors on Friday morning, Benzinga reports. The firm currently has a buy rating on the stock. Other equities research analysts have also issued reports about the company. BTIG Research began coverage […]